Please enter exact key words
A novel Humanized Frizzled-7-targeting Antibody

for Cancer Therapy

Home / Available Projects / A novel Humanized Frizzled-7-targeting Antibody
Drug Name GPCR-targeted Project 016

Frizzled 7 (FZD7) is a critical receptor for Wnt signaling, which binds to Wnt proteins to activate either canonical or noncanonical Wnt signaling pathways. The Wnt/β-catenin signaling pathway is involved in the regulation of cell proliferation, differentiation, migration, apoptosis, and survival, and has been shown to be dysregulated in cancers.
A novel humanized anti-FZD7 antibody is being developed at early stage for the treatment of cancers in which FZD7 is upregulated, such as colon, pancreatic and gastric cancers.

Target Frizzled 7 (FZD7)
Drug Modality Monoclonal antibody
Indication Cancers
Product Category Biologic
Mechanism of Action Frizzled 7 antagonists
Status Preclinical
Patent Granted

More Detail Available Upon Request

We look forward to hearing from you.

Our customer service representatives are available 24 hours a day, from Monday to Sunday Online Inquiry

Protheragen's business is growing rapidly after founded in Ronkonkoma, New York. Our business has evolved from the initial intermediary service to encompass segments in equity investment and program incubation.

Protheragen Inc.